Genmab — Februar 2024

[Sukkeralf]

Scroll down to the right study

[Sukkeralf]

But maybe its the title thats wrong

[E_L]

well, it would fit Jan's comment:

af Jan Van de Winkel
GEN1056 is going to be positioned very broadly as a potential combination therapy for multiple other Genmab next generation antibody therapeutics.

[E_L]

Major bank sees positive signals in Lundbeck's MSA study despite missed endpoint https://medwatch.com/News/Pharma___Biotech/article16812127.ece

[Sukkeralf]

But why keep it a secret - others are pursuing the same…….
unless Genmab has another nice new feature.

[E_L]

don't know...

[E_L]

Circio is testing TG01 mutant RAS cancer vaccine in combination with daratumumab and nivolumab in non-small cell lung cancer (NSCLC) https://www.circio.com/en/the-first-patient-has-been-dosed-in-circios-tg01-triple-combination-study/

[havana]

Jeg har nogle 100'er GENMAB aktier fra 2009. De skal sælges i år kva min alder.
Skal jeg sælge inden årsregnskabet?

[Bella1]

Nå,nå, en god fredagsnyhed, - hvor langt skal vi så ned?

[lahn1]

Jeg håber så sandeligt at mine mabber er stegt en del inden året udgang. Ville måske sælge før Hex-CD38 H2H data i 2H-24, det kan jo gå begge veje.

[bikube]

Hvis jeg husker rigtigt, er det en 50/50 aftale, så er det da fint med Pfizer at dele med, de har muskler til at få det fremad.

[bikube]

havana - Jeg ville aldrig sælge alt på en gang, sælg evt. 20% hver anden måned, hvis du sælger alt nu, misser du måske et stort overskud.

[ProinvestorNEWS]

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastisk Cervical Cancer https://www.proinvestor.com/investornyt/1111713/tisotumab-vedotin-marketing-authorization-application-validated-by-european-medicines-agency-for-treatment-of-recurrent-or-meta

[ProinvestorNEWS]

Genmab: EMA vil behandle ansøgning om godkendelse af middel mod livmoderhalskræft https://www.proinvestor.com/investornyt/1111730/genmab-ema-vil-behandle-ansogning-om-godkendelse-af-middel-mod-livmoderhalskraeft

[Vitus]

Reagerer overhovedet ikke på det…..men der er jo heller ikke kommet noget penge i kassen på det endnu…

[E_L]

Abbvie reports Epkinly Q4 '23 US12 Intl 5 Total 17, Full year '23 : 26 / 5 / 31 . U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories. This compares to Q3 Genmab comment around $22 million in net sales for the quarter and $28 million year-to-date.

17

[Vitus]

Nå, den kunne godt reagere

[E_L]

So the US number we have to double I think, the International i am not sure. But since it is such a small number it won't matter much. So it is total 52 + 10 = 62 or 52 + 5 = 57 total (T)Epkinly for the year

[Solsen]

Wasnt the deal that Genmab report US sales ?

[Solsen]

This collaboration will provide for the joint development and commercialization of the three bispecific antibody therapeutic candidates. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales.